Federal Register Notice: FDA is making available a Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products. The guidance amends the 1/02 document of the same title by: incorporating donor deferral recommendations for donors who have received a transfusion of blood or blood components in France since 1980, providing updated scientific information on CJD and vCJD, revising labeling recommendations for whole blood and blood components intended for transfusion, and recognizing a full Donor History Questionnaire Version 1.3 from AABB (an international, not-for-profit association representing individuals and institutions involved in the field of transfusion medicine and cellular therapies) as an acceptable mechanism for collection of donor history information. To download this guidance, click here. To view this notice, click here.